Par Income Tax Expense vs Net Income Analysis

PAR Stock

290.40 11.35 4.07%

Par Drugs financial indicator trend analysis is much more than just breaking down Par Drugs And prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Par Drugs And is a good investment. Please check the relationship between Par Drugs Income Tax Expense and its Net Income accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Par Drugs And. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Income Tax Expense vs Net Income

Income Tax Expense vs Net Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Par Drugs And Income Tax Expense account and Net Income. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Par Drugs' Income Tax Expense and Net Income is 0.98. Overlapping area represents the amount of variation of Income Tax Expense that can explain the historical movement of Net Income in the same time period over historical financial statements of Par Drugs And, assuming nothing else is changed. The correlation between historical values of Par Drugs' Income Tax Expense and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Tax Expense of Par Drugs And are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Income Tax Expense i.e., Par Drugs' Income Tax Expense and Net Income go up and down completely randomly.

Correlation Coefficient

0.98

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Income Tax Expense

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Par Drugs And financial statement analysis. It represents the amount of money remaining after all of Par Drugs And operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Most indicators from Par Drugs' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Par Drugs And current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Par Drugs And. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

As of November 30, 2024, Selling General Administrative is expected to decline to about 11.4 M. In addition to that, Tax Provision is expected to decline to about 29.1 M

	2021	2022	2023	2024 (projected)
Total Revenue	742.0M	951.0M	956.4M	669.2M
Depreciation And Amortization	32.8M	32.3M	34.4M	33.2M

Total Revenue Depreciation And Amortization

Par Drugs fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Other Liab
Total Assets		-0.65	0.72	-0.53	0.95	-0.31	-0.88	0.89	0.32	0.9	-0.32	-0.56	0.44	0.9	0.73	0.49	-0.8	-0.23	0.55	0.52	-0.71	0.98	-0.74	0.93	-0.26	0.82
Short Long Term Debt Total	-0.65		-0.41	0.94	-0.85	0.76	0.87	-0.7	-0.22	-0.68	0.76	0.23	0.02	-0.68	-0.81	-0.59	0.93	0.74	-0.33	-0.95	0.98	-0.78	0.96	-0.8	-0.18	-0.88
Other Current Liab	0.72	-0.41		-0.23	0.67	-0.22	-0.57	0.59	0.66	0.53	-0.23	-0.35	0.45	0.53	0.81	0.3	-0.59	0.15	0.03	0.23	-0.47	0.72	-0.51	0.74	-0.38	0.42
Total Current Liabilities	-0.53	0.94	-0.23		-0.74	0.79	0.83	-0.7	-0.05	-0.65	0.79	0.27	0.2	-0.65	-0.69	-0.66	0.89	0.78	-0.47	-0.92	0.96	-0.63	0.93	-0.69	-0.07	-0.87
Total Stockholder Equity	0.95	-0.85	0.67	-0.74		-0.49	-0.94	0.89	0.29	0.87	-0.5	-0.47	0.28	0.87	0.83	0.6	-0.92	-0.43	0.5	0.73	-0.89	0.98	-0.89	0.97	-0.14	0.92
Property Plant And Equipment Net	-0.31	0.76	-0.22	0.79	-0.49		0.71	-0.58	-0.32	-0.58	1.0	0.19	0.15	-0.58	-0.63	-0.38	0.76	0.78	-0.37	-0.77	0.75	-0.43	0.79	-0.44	-0.22	-0.62
Net Debt	-0.88	0.87	-0.57	0.83	-0.94	0.71		-0.96	-0.31	-0.95	0.71	0.53	-0.18	-0.95	-0.81	-0.6	0.97	0.58	-0.64	-0.78	0.92	-0.91	0.95	-0.9	0.12	-0.95
Retained Earnings	0.89	-0.7	0.59	-0.7	0.89	-0.58	-0.96		0.29	0.98	-0.59	-0.61	0.2	0.98	0.72	0.61	-0.89	-0.42	0.75	0.61	-0.8	0.87	-0.84	0.86	-0.33	0.89
Accounts Payable	0.32	-0.22	0.66	-0.05	0.29	-0.32	-0.31	0.29		0.25	-0.32	-0.03	0.24	0.25	0.66	0.18	-0.35	0.0	-0.17	0.16	-0.23	0.35	-0.33	0.42	-0.29	0.14
Cash	0.9	-0.68	0.53	-0.65	0.87	-0.58	-0.95	0.98	0.25		-0.59	-0.64	0.29	1.0	0.66	0.48	-0.85	-0.45	0.76	0.6	-0.76	0.88	-0.8	0.81	-0.19	0.87
Non Current Assets Total	-0.32	0.76	-0.23	0.79	-0.5	1.0	0.71	-0.59	-0.32	-0.59		0.2	0.14	-0.59	-0.63	-0.38	0.77	0.78	-0.38	-0.77	0.76	-0.44	0.79	-0.45	-0.21	-0.63
Non Currrent Assets Other	-0.56	0.23	-0.35	0.27	-0.47	0.19	0.53	-0.61	-0.03	-0.64	0.2		-0.69	-0.64	-0.29	0.09	0.44	-0.09	-0.48	0.0	0.34	-0.48	0.36	-0.49	0.31	-0.59
Other Assets	0.44	0.02	0.45	0.2	0.28	0.15	-0.18	0.2	0.24	0.29	0.14	-0.69		0.29	0.17	-0.51	-0.1	0.38	-0.05	-0.26	0.01	0.39	-0.02	0.31	0.0	0.2
Cash And Short Term Investments	0.9	-0.68	0.53	-0.65	0.87	-0.58	-0.95	0.98	0.25	1.0	-0.59	-0.64	0.29		0.66	0.48	-0.85	-0.45	0.76	0.6	-0.76	0.88	-0.8	0.81	-0.19	0.87
Net Receivables	0.73	-0.81	0.81	-0.69	0.83	-0.63	-0.81	0.72	0.66	0.66	-0.63	-0.29	0.17	0.66		0.57	-0.88	-0.38	0.18	0.7	-0.84	0.81	-0.87	0.88	-0.21	0.72
Common Stock Shares Outstanding	0.49	-0.59	0.3	-0.66	0.6	-0.38	-0.6	0.61	0.18	0.48	-0.38	0.09	-0.51	0.48	0.57		-0.64	-0.43	0.5	0.65	-0.67	0.52	-0.66	0.63	-0.45	0.57
Non Current Liabilities Total	-0.8	0.93	-0.59	0.89	-0.92	0.76	0.97	-0.89	-0.35	-0.85	0.77	0.44	-0.1	-0.85	-0.88	-0.64		0.6	-0.5	-0.84	0.97	-0.87	0.98	-0.9	0.1	-0.94
Inventory	-0.23	0.74	0.15	0.78	-0.43	0.78	0.58	-0.42	0.0	-0.45	0.78	-0.09	0.38	-0.45	-0.38	-0.43	0.6		-0.41	-0.89	0.67	-0.35	0.69	-0.3	-0.46	-0.57
Other Current Assets	0.55	-0.33	0.03	-0.47	0.5	-0.37	-0.64	0.75	-0.17	0.76	-0.38	-0.48	-0.05	0.76	0.18	0.5	-0.5	-0.41		0.37	-0.44	0.49	-0.47	0.43	-0.3	0.61
Other Stockholder Equity	0.52	-0.95	0.23	-0.92	0.73	-0.77	-0.78	0.61	0.16	0.6	-0.77	0.0	-0.26	0.6	0.7	0.65	-0.84	-0.89	0.37		-0.9	0.65	-0.9	0.65	0.26	0.77
Total Liab	-0.71	0.98	-0.47	0.96	-0.89	0.75	0.92	-0.8	-0.23	-0.76	0.76	0.34	0.01	-0.76	-0.84	-0.67	0.97	0.67	-0.44	-0.9		-0.81	0.99	-0.86	0.0	-0.93
Total Current Assets	0.98	-0.78	0.72	-0.63	0.98	-0.43	-0.91	0.87	0.35	0.88	-0.44	-0.48	0.39	0.88	0.81	0.52	-0.87	-0.35	0.49	0.65	-0.81		-0.83	0.96	-0.14	0.86
Short Term Debt	-0.74	0.96	-0.51	0.93	-0.89	0.79	0.95	-0.84	-0.33	-0.8	0.79	0.36	-0.02	-0.8	-0.87	-0.66	0.98	0.69	-0.47	-0.9	0.99	-0.83		-0.86	0.03	-0.92
Common Stock	0.93	-0.8	0.74	-0.69	0.97	-0.44	-0.9	0.86	0.42	0.81	-0.45	-0.49	0.31	0.81	0.88	0.63	-0.9	-0.3	0.43	0.65	-0.86	0.96	-0.86		-0.31	0.88
Current Deferred Revenue	-0.26	-0.18	-0.38	-0.07	-0.14	-0.22	0.12	-0.33	-0.29	-0.19	-0.21	0.31	0.0	-0.19	-0.21	-0.45	0.1	-0.46	-0.3	0.26	0.0	-0.14	0.03	-0.31		-0.1
Other Liab	0.82	-0.88	0.42	-0.87	0.92	-0.62	-0.95	0.89	0.14	0.87	-0.63	-0.59	0.2	0.87	0.72	0.57	-0.94	-0.57	0.61	0.77	-0.93	0.86	-0.92	0.88	-0.1

Click cells to compare fundamentals

Par Drugs Account Relationship Matchups

Par Drugs fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	601.2M	763.8M	786.9M	888.7M	1.0B	763.9M
Short Long Term Debt Total	231.3M	115.8M	60.1M	83.2M	74.9M	139.5M
Other Current Liab	2.5M	19.7M	42.0M	59.0M	21.1M	20.4M
Total Current Liabilities	108.4M	159.8M	148.6M	139.9M	124.4M	123.4M
Total Stockholder Equity	406.1M	522.1M	598.8M	712.4M	856.3M	483.9M
Property Plant And Equipment Net	351.4M	343.7M	343.5M	386.9M	413.3M	305.2M
Net Debt	(13.7M)	(128.4M)	(162.1M)	(222.4M)	(366.5M)	(348.2M)
Retained Earnings	175.3M	291.3M	368.0M	481.6M	625.5M	656.8M
Accounts Payable	62.0M	67.2M	106.6M	80.9M	53.6M	75.1M
Cash	73.8M	211.6M	162.1M	222.4M	366.5M	384.9M
Non Current Assets Total	359.0M	352.0M	351.3M	394.3M	419.9M	311.6M
Non Currrent Assets Other	7.1M	8.2M	7.6M	7.3M	6.4M	6.3M
Other Assets	7.1M	7.6M	7.6M	7.3M	8.4M	5.1M
Cash And Short Term Investments	73.8M	211.6M	162.1M	222.4M	366.5M	384.9M
Net Receivables	139.2M	126.2M	217.4M	218.2M	137.1M	145.8M
Liabilities And Stockholders Equity	601.2M	763.8M	786.9M	888.7M	1.0B	763.9M
Non Current Liabilities Total	86.6M	81.9M	39.6M	36.4M	35.4M	33.6M
Inventory	29.2M	30.0M	47.1M	53.8M	44.2M	34.4M
Other Current Assets	(1.0)	35.1M	9.1M	(1K)	187.9M	197.3M
Other Stockholder Equity	99.7M	168.2M	168.2M	106.7M	122.7M	92.7M
Total Liab	195.0M	241.7M	188.1M	176.3M	159.8M	203.6M
Total Current Assets	242.2M	411.9M	435.6M	494.4M	596.2M	335.4M
Short Term Debt	13.9M	39.3M	90K	623K	(51K)	(48.5K)
Current Deferred Revenue	30.0M	46.5M	90K	623K	51K	48.5K
Other Liab	37.5M	40.4M	38.0M	39.5M	45.5M	41.5M
Net Tangible Assets	290.3M	406.1M	522.1M	598.8M	688.6M	433.3M
Net Invested Capital	466.3M	598.5M	598.8M	712.4M	856.3M	631.7M
Net Working Capital	133.7M	252.1M	287.1M	354.5M	471.8M	495.4M
Property Plant Equipment	363.4M	351.4M	344.3M	343.5M	309.2M	286.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Other Information on Investing in Par Stock

Balance Sheet is a snapshot of the financial position of Par Drugs And at a specified time, usually calculated after every quarter, six months, or one year. Par Drugs Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Par Drugs and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Par currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Par Income Tax Expense vs Net Income Analysis

Income Tax Expense vs Net Income

Income Tax Expense vs Net Income Correlation Analysis

Correlation Coefficient

Income Tax Expense

Net Income

Par Drugs fundamental ratios Correlations

Par Drugs Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Par Drugs fundamental ratios Accounts

Also Currently Popular

Other Information on Investing in Par Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Short Term Debt	+ 0.99	Total Liab
Total Current Assets	+ 0.98	Total Assets
Total Liab	+ 0.98	Short Long Term Debt Total
Total Current Assets	+ 0.98	Total Stockholder Equity

Retained Earnings	- 0.96	Net Debt
Other Liab	- 0.95	Net Debt
Cash And Short Term Investments	- 0.95	Net Debt
Cash	- 0.95	Net Debt
Other Stockholder Equity	- 0.95	Short Long Term Debt Total
Other Liab	- 0.94	Non Current Liabilities Total